JP2008523098A5 - - Google Patents

Download PDF

Info

Publication number
JP2008523098A5
JP2008523098A5 JP2007545685A JP2007545685A JP2008523098A5 JP 2008523098 A5 JP2008523098 A5 JP 2008523098A5 JP 2007545685 A JP2007545685 A JP 2007545685A JP 2007545685 A JP2007545685 A JP 2007545685A JP 2008523098 A5 JP2008523098 A5 JP 2008523098A5
Authority
JP
Japan
Prior art keywords
nucleoside
prodrug
pharmaceutically acceptable
base
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007545685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008523098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/044709 external-priority patent/WO2006063281A2/en
Publication of JP2008523098A publication Critical patent/JP2008523098A/ja
Publication of JP2008523098A5 publication Critical patent/JP2008523098A5/ja
Withdrawn legal-status Critical Current

Links

JP2007545685A 2004-12-10 2005-12-08 ウィルス感染および異常細胞増殖の治療用の２′および３′−置換シクロブチルヌクレオシド類縁体 Withdrawn JP2008523098A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63487504P 2004-12-10 2004-12-10
PCT/US2005/044709 WO2006063281A2 (en) 2004-12-10 2005-12-08 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation

Publications (2)

Publication Number Publication Date
JP2008523098A JP2008523098A (ja) 2008-07-03
JP2008523098A5 true JP2008523098A5 (enExample) 2009-01-29

Family

ID=36578634

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007545685A Withdrawn JP2008523098A (ja) 2004-12-10 2005-12-08 ウィルス感染および異常細胞増殖の治療用の２′および３′−置換シクロブチルヌクレオシド類縁体

Country Status (9)

Country Link
US (2) US7495006B2 (enExample)
EP (1) EP1828145A4 (enExample)
JP (1) JP2008523098A (enExample)
CN (1) CN101115725A (enExample)
AU (1) AU2005313912A1 (enExample)
BR (1) BRPI0518984A2 (enExample)
CA (1) CA2590115A1 (enExample)
MX (1) MX2007006961A (enExample)
WO (1) WO2006063281A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US7635479B2 (en) * 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
MX2007006961A (es) 2004-12-10 2007-10-04 Univ Emory Analogos nucleosidos de ciclobutilo 2' y 3'-sustituidos para el tratamiento de infeccciones virales y proliferacion celular anormal.
US20090318380A1 (en) * 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2010032147A2 (en) 2008-09-19 2010-03-25 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
US8664401B2 (en) 2009-12-16 2014-03-04 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
EA024782B1 (ru) 2011-03-07 2016-10-31 Пфайзер Инк. Производные фторпиридинона, полезные в качестве антибактериальных агентов
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
CA2830866A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
MX2013011526A (es) 2011-04-08 2013-12-06 Pfizer Derivados de isoxazol utiles como agentes antibacteriales .
EA024297B1 (ru) 2011-12-20 2016-09-30 Рибосайенс Ллк 2',4'-дифтор-2'-метилзамещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
SG11201403086YA (en) 2011-12-20 2014-07-30 Hoffmann La Roche 4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
EA201592185A1 (ru) 2013-05-16 2016-05-31 Рибосайенс Ллк 4'-азидо, 3'-дезокси-3'-фторзамещенные нуклеозидные производные
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
MY186547A (en) 2013-05-16 2021-07-26 Riboscience Llc 4?-fluoro-2?-methyl substituted nucleoside derivatives
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
TW201625569A (zh) 2014-11-19 2016-07-16 艾克泰聯製藥有限公司 抗菌性苯并噻唑衍生物
GEAP202215528A (en) 2015-03-06 2022-11-10 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
BR112019004297A2 (pt) 2016-09-07 2019-05-28 Atea Pharmaceuticals Inc método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
CN110049767B (zh) * 2016-10-03 2023-04-04 艾库斯生物科学有限公司 腺苷5′-核苷酸酶的抑制剂
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
WO2019060740A1 (en) 2017-09-21 2019-03-28 Riboscience Llc 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法
CN119431343A (zh) * 2024-11-04 2025-02-14 河南大学 一种m6A去甲基化酶ALKBH1小分子抑制剂、合成方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855466A (en) * 1987-12-28 1989-08-08 E. R. Squibb & Sons, Inc. Purinyl cyclobutanes
EP0330992A3 (en) * 1988-02-29 1991-11-06 Nippon Kayaku Kabushiki Kaisha Novel cyclobutane derivatives, processes for their preparation and pharmaceutical compositions comprising them
US5130462A (en) * 1988-03-30 1992-07-14 E. R. Squibb & Sons, Inc. Cyclobutane derivatives
US5185459A (en) * 1988-03-30 1993-02-09 E. R. Squibb & Sons Inc. Bis protected (hydroxymethyl)cyclobutanols
US5126345A (en) * 1988-03-30 1992-06-30 E. R. Squibb & Sons, Inc. Bis (hydroxymethyl) cyclobutyl triazolopyrimidines
IL92096A0 (en) * 1988-10-25 1990-07-12 Abbott Lab Carboxylic nucleoside analogs
US4918075A (en) * 1988-12-20 1990-04-17 E. R. Squibb & Sons, Inc. Purinyl and pyrimidinyl cyclobutanes and their use as antiviral agents
US5324730A (en) * 1990-05-24 1994-06-28 Nippon Kayaku Kabushiki Kaisha Phenoxyphosphoryloxymethyl cyclobutyl purines
CA2042931A1 (en) * 1990-05-24 1991-11-25 Robert Zahler Fluorinated bis (hydroxymethyl) cyclobutyl purines and pyrimidines
US5166397A (en) * 1990-09-20 1992-11-24 Nippon Kayaku Kabushiki Kaisha Process for producing optically active cyclobutylamines
US20040229839A1 (en) * 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
MX2007006961A (es) * 2004-12-10 2007-10-04 Univ Emory Analogos nucleosidos de ciclobutilo 2' y 3'-sustituidos para el tratamiento de infeccciones virales y proliferacion celular anormal.

Similar Documents

Publication Publication Date Title
JP2008523098A5 (enExample)
JP7786743B2 (ja) ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用
KR102453808B1 (ko) 필로비리다에 바이러스 감염을 치료하는 방법
IL170894A (en) Antiviral phosphonate analogs
JP2010501584A5 (enExample)
CA2632626C (en) Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection
JP2017537158A5 (enExample)
DE69929060D1 (de) Beta-l-2'-deoxynukleoside für die behandlung von hepatitis b virus
CN1416431A (zh) 核苷化合物及其应用
JP2008255121A (ja) 抗ｂ型肝炎ウイルス活性を有するヌクレオシド
JP2004513070A5 (enExample)
JP2010510301A (ja) 化合物
JP2004533401A5 (enExample)
CN114867351B (zh) 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途
TW202233203A (zh) 磷脂化合物及其用途
JP2001510843A5 (enExample)
WO2017106710A1 (en) Nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2003532640A5 (enExample)
JP2024038012A (ja) アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
US20190085013A1 (en) Nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2003520783A5 (enExample)
BR0314695A (pt) Composto, processo para preparar um composto, processo para preparar um estereoisÈmero de um composto, composição para o tratamento de doenças virais, e, composição para o tratamento da hepatite b
JP2005514440A5 (enExample)
JP2002533470A5 (enExample)
EP1812456A2 (en) ß-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES